PPLPHARMA
CAUTIONPiramal Pharma Limited
Pharma · NSE
52W Low
₹132
+8.7% from low
52W High
₹228
-37.0% from high
Valuation Gauge
Current Price
₹144
Fair Value
—
Fair Value Analysis
—
Loss-making company — EPS ₹-1.22, PAT ₹-163Cr, Revenue ₹8872Cr. Standard valuation formulas (DCF/Graham/Lynch) are not applicable for loss-making companies. Monitor for return to profitability.
Price vs Market
Shareholding Pattern
Stock Health Score
Weak Fundamentals
Profitability
Negative EPS of ₹-1.2 — company is currently loss-making
Debt & Leverage
D/E ratio of 0.6x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 60.0x trades at a significant premium to Pharma sector median (42x)
Cash Flow
FCF margin of 2.5% — thin cash generation, watch capex trends
Earnings Growth
5yr EPS CAGR of -37.6% — severe earnings decline
Dividend
Dividend yield of 0.1% is symbolic — low but positive
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
2.1%
Free cash flow / market cap
Revenue Growth (YoY)
-2.9%
Year-on-year revenue change
Profit Growth (YoY)
-3500.0%
Year-on-year PAT change
Operating Cash Flow
₹892 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹-1.2
P/E Ratio
60x
P/B Ratio
2.3x
ROE
-2%
ROCE
7%
Debt / Equity
0.6x
Beta
0.19
Div Yield
0.1%
FCF (Cr)
₹228 Cr
Revenue (Cr)
₹9,061 Cr
EPS Growth 5Y
-37.7%
Mkt Cap (Cr)
₹18,825 Cr
52W High
₹228.5
52W Low
₹132.3
Book Value/Share
₹60.6
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹8.9K Cr | ₹1.0K Cr | 12.0% | ₹-164 Cr | ₹-1.22 |
| 2025-03-31 | ₹9.2K Cr | ₹1.4K Cr | 16.0% | ₹91 Cr | ₹0.69 |
| 2024-03-31 | ₹8.2K Cr | ₹1.2K Cr | 15.0% | ₹18 Cr | ₹0.13 |
| 2023-03-31 | ₹7.1K Cr | ₹629 Cr | 9.0% | ₹-186 Cr | ₹-1.41 |
| 2022-03-31 | ₹6.6K Cr | ₹950 Cr | 14.0% | ₹376 Cr | — |
| 2021-03-31 | ₹6.3K Cr | ₹1.4K Cr | 23.0% | ₹835 Cr | — |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86 | ₹469.7 | +81.7% | 7.3 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹79.5 | ₹237.8 | +66.6% | 19.6 | 5.2% | FAIRLY_VALUED |
Kilitch Drugs (India) Limited | ₹132.7 | ₹321 | +58.7% | 17.7 | 9.4% | UNDERVALUED |
Bal Pharma Limited | ₹69 | ₹147.5 | +53.2% | 12.8 | 12.6% | FAIRLY_VALUED |
Zydus Lifesciences | ₹868 | ₹1,502.2 | +42.2% | 17.6 | 19.9% | UNDERVALUED |
Natco Pharma | ₹1,030 | ₹1,597 | +35.5% | 11.8 | 18.0% | UNDERVALUED |
Jagsonpal Pharmaceuticals Limited | ₹190.6 | ₹275.2 | +30.7% | 30.8 | 20.1% | UNDERVALUED |
Lupin | ₹2,280 | ₹3,112 | +26.7% | 22.4 | 23.8% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant